

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE		Application Number	10/521,821
STATEMENT BY APPLICANT		Filing Date	January 21, 2005
(use as many sheets as necessary)		First Named Inventor	R.B. Toupenca et al.
		Group Art Unit	1625
		Examiner Name	ZNDAVIS
Sheet 1	of 6	Attorney Docket Number	21175YP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
md A 					

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
md			GB 2289276		Merck & Co., Inc.	11/15/1995
			EP 0 250 131		Borden, Inc.	11/21/1991
			EP 0 737 685		Adir Et Compagnie	07/19/2000
			WO 98/46609		Abbott Laboratories	10/22/1998
			WO 96/11929		SmithKline Beecham PLC	04/25/1996
			WO 96/23783		SmithKline Beecham PLC	08/08/1996
			WO 97/08167		SmithKline Beecham PLC	03/06/1997
			WO 99/03859		Astra Aktiebolag	01/28/1999
			WO 97/37989		SmithKline Beecham PLC	10/16/1997
			WO 97/05139		Abbott Laboratories	02/13/1997

Examiner Signature	<i>Anna W. Davis</i>	Date Considered	12/5/2005
--------------------	----------------------	-----------------	-----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND-TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

COMPLETE IF KNOWN

Application Number	10/521,821
Filing Date	January 21, 2005
First Named Inventor	R.B. Toupence et al.
Group Art Unit	1625
Examiner Name	ZINNA N DAVIS
Attorney Docket Number	21175YP

APR 27 1968 (use as many sheets as necessary)

Sheet	2	of	6
-------	---	----	---

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number <i>(if known)</i>		
md			JP1993086064A	Yoshitomi Pharmaceutical Industries Ltd./Japan Tobacco Inc.	04/06/1993
			JP1993004989A	Yoshitomi Pharmaceutical Industries Ltd	01/14/1993
			JP1995053562A	Yoshitomi Pharmaceutical Industries Ltd	02/28/1995
			WO 92/03427	Yoshitomi Pharmaceutical Industries Ltd	03/05/1992
			WO 2004/060882	AstraZeneca AB	07/22/2004
			WO 2004/013120	F. Hoffman-La Roche AG	02/12/2004
			WO 03/027114	Bayer Pharmaceuticals Corporation	04/03/2003
			WO 99/02499	Japan Tobacco Co.	01/21/1999
md			WO 01/58450	Sanofi-Synthelabo	08/16/2001
			WO 98/32441	Sanofi	07/30/1998

**Examiner
Signature**

Date Considered

12/5/2005

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

STATEMENT BY APPLICANT

APR 27 2005
rise as m

Use as many sheets as necessary)

Sheet

TRADEMARK

of

6

Application Number

10/521,821

Filing Date

January 21, 2005

First Named Inventor

R.B. Toupence et al.

Group Art Unit

1625

Examiner Name

ZNDAVIS

Attorney Docket Number

21175YP

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number <i>(if known)</i>		
md ↑			WO 2003/082191	Merck & Co., Inc.	10/09/2003
			WO 2003/086288	Merck & Co., Inc.	10/23/2003
			WO 03/063781	Merck & Co., Inc.	08/07/2003
			WO 03/007887	Merck & Co., Inc.	01/30/2003
			WO 2003/077847	Merck & Co., Inc.	09/25/2003
			WO 2003/082190	Merck & Co., Inc.	10/09/2003
			WO 2004/087704	AstraZeneca AB	10/14/2004
↓ md			WO 2005/000301	F. Hoffman-LaRoche AG	01/06/2005
			WO 96/02248	Eli Lilly and Company	02/01/1996
			WO 2004/000832	Akzo Nobel N.V.	12/31/2003

**Examiner
Signature**

Final Oavis

Date Considered

12/5/2005

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

APR 27. 2005


COMPLETE IF KNOWN

Sheet 5 of 6

[illegible][illegible]

12/5/2005

Computer generated form "IDS Form" (IDS Folder), Merrick & Co., Inc., 09/06/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use many sheets as necessary)			COMPLETE IF KNOWN		
			Application Number	10/521,821	
			Filing Date	January 21, 2005	
			First Named Inventor	R.B. Toupence et al.	
			Group Art Unit	1625	
			Examiner Name	ZN DAVIS	
Sheet	6	of	6	Attorney Docket Number	21175YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
nod	AA	Taylor et al., Tetrahedron, Vol. 43 (1987), pp. 5145-5158, "Intramolecular diels-alder reactions of 1,2,4-triazines"
	AB	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
	AC	Petit et al., Emerging Drugs, Vol. 3 (1998), pp. 39-53, "The therapeutic applications of cannabinoid agonists and antagonists"
	AD	Grundy, Expert Opin. Investig. Drugs, Vol. 11 (2002), pp. 1365-1374, "The therapeutic potential of the cannabinoids in neuroprotection"
	AE	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
	AF	Adam et al., Exp. Opin. Ther. Patents, Vol. 12 (2002), pp. 1475-1489, "Recent advances in the cannabinoids"
	AG	Le Foll et al., J. Pharm. & Exper. Ther., Vol. 312 (2005), pp. 875-883, "Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence"
	AH	Xiang et al, Ann. Reports in Med. Chem., Vol. 34 (1999), pp. 199-208, "Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists"
nod	AI	Database Chemcats, AN:2003:951109, 2003

Examiner Signature	<i>Zina W. Davis</i>	Date Considered	12/5/2005
--------------------	----------------------	-----------------	-----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003